Celcuity breast cancer win; Odyssey plans $205M IPO; Latus Bio extends Series A
Celcuity’s breast cancer drug wins again: The company said two regimens with its experimental drug gedatolisib succeeded in PIK3CA mutant patients as part of its Phase 3 trial. Last year ...
ORIGINAL SOURCE →via Endpoint News
ADVERTISEMENT
⚡ STAY AHEAD
Events like this, convergence-verified across 689 sources, land in your inbox every Sunday. Free.
GET THE SUNDAY BRIEFING →RELATED · finance
- [FINANCE] China Orders Firms to Defy U.S. Sanctions in Escalation Over Iran Oil Trade
- [FINANCE] US Dollar Majors, Gold, Bitcoin, Equities Weekly Technical Outlook - FOREX.com
- [FINANCE] IRTC Stock Up on Q1 Earnings & Revenue Beat, FY26 Outlook Raised - Zacks Investment Research
- [FINANCE] Mohawk Industries stock hits 52-week low at $94.41
- [FINANCE] Louisiana-Pacific stock hits 52-week low at 68.84 USD
- [FINANCE] DWS Group Q1 2026 slides: earnings beat on cost discipline, stock surges 12%